Sergio De Filippi

Biographic Data

ID4813278
NAMESergio De Filippi
GIVEN NAMESSergio
FAMILY NAMEDe Filippi
SIGNATUREDE FILIPPI S
AFFILIATIONSVilla Melitta
ORCID0000-0002-6521-3379
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS1
WORKS AS AUTHOR6
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2018
LATEST PUBLICATION YEAR2023
H-INDEX1

  • Brexpiprazole in patients with schizophrenia with or without substance use disorder

    Open AccessGinevra Lombardozzi, Giada Trovini et al.ARTICLEFrontiers in Psychiatry2023

    Treatment with brexpiprazole for 6 months improved psychotic symptoms in patients with schizophrenia, independently from whether they belonged to the SUD or the non-SUD group; hence, SUD comorbidity did not confer treatment resistance to brexpiprazole. Furthermore, in the SUD group, we observed reduced substance craving

  • Vulnerabilities in Mental Health due to Covid-19 Pandemic

    Open AccessAlessandra De Rose, Maria Felice Arezzo et al.ARTICLESocial Indicators Research2023Cited by: 1References: 2

    COVID-19 pandemic has exacerbated the pre-existing vulnerabilities and inequalities in societies. In this paper we analyse the categories that have suffered more than others from the pandemic and the restrictions on social life in terms of mental health. We rely on the Serendipity project based on a survey administered between November 2021 and February 2022 to a sample of Italian physicians (n = 1281). The survey aimed to assess the perception o…

  • Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression

    Open AccessGiulio Perugi, Paola Calò et al.ARTICLEFrontiers in Psychiatry2021

    Introduction: Treatment-resistant depression (TRD) is a debilitating condition affecting 20-30% of patients with major depressive disorders (MDD). Currently, there is no established standard of care for TRD, and wide variation in the clinical approach for disease management has been documented. Real-world data could help describe TRD clinical features, disease burden, and treatment outcome and identify a potential unmet medical need. Methods: We …

  • Case Report

    Open AccessAlessandro Vento, Alessandro E Vento et al.ARTICLEFrontiers in Psychiatry2021

    Kratom or Mitragyna speciosa (Korth.) is an evergreen tree of the coffee family native to South-East Asia and Australasia. It is used by locals recreationally to induce stimulant and sedative effects and medically to soothe pain and opiate withdrawal. Its leaves are smoked, chewed, or infused, or ground to yield powders or extracts for use as liquids. It contains more than 40 alkaloids; among these, mitragynine and 7-hydroxymitragynine are endowe…

  • Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

    Open AccessGloria Giordano, Lorenzo Tomassini et al.ARTICLEFrontiers in Psychiatry2020

    Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once month…

  • Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy

    Open AccessMassimo Clerici, Andrea De Bartolomeis et al.ARTICLEFrontiers in Psychiatry2018

    Patients with severe psychotic disorders such as schizophrenia, schizoaffective, and bipolar disorders frequently suffer from concomitant substance use disorders (SUDs)-Dual Disorder (DD) patients. In order to better understand current practices for management of patients with psychotic episodes and concomitant SUD in Italy, we carried out a survey of psychiatrists on current routine practice among prescribers. These aspects can help to identify …